Stocks: Zeltiq Aesthetics Inc (ZLTQ) Given Consensus Recommendation of “Hold” by Analysts

Stocks: Zeltiq Aesthetics Inc (ZLTQ) Given Consensus Recommendation of “Hold” by Analysts

Zeltiq Aesthetics Inc (NASDAQ:ZLTQ) has been given an average recommendation of “Hold” by the thirteen research firms that are covering the company. Ten investment analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $52.63.

ZLTQ has been the subject of several research analyst reports. Aegis reiterated a “hold” rating and issued a $56.00 price objective on shares of Zeltiq Aesthetics in a report on Monday, April 24th. Zacks Investment Research upgraded Zeltiq Aesthetics from a “hold” rating to a “buy” rating and set a $63.00 price objective for the company in a report on Thursday, April 13th. Leerink Swann cut Zeltiq Aesthetics from an “outperform” rating to a “market perform” rating in a report on Tuesday, February 14th. Canaccord Genuity reiterated a “hold” rating and issued a $56.50 price objective on shares of Zeltiq Aesthetics in a report on Friday, March 10th. Finally, Northcoast Research cut Zeltiq Aesthetics from a “buy” rating to a “neutral” rating in a report on Tuesday, February 14th.

Zeltiq Aesthetics (NASDAQ:ZLTQ) opened at 56.48 on Friday. Zeltiq Aesthetics has a 1-year low of $23.58 and a 1-year high of $56.50. The company has a 50 day moving average price of $56.05 and a 200-day moving average price of $46.95.

In related news, SVP Bradley Hauser sold 3,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 21st. The stock was sold at an average price of $55.64, for a total transaction of $166,920.00. Following the completion of the transaction, the senior vice president now owns 49,301 shares of the company’s stock, valued at approximately $2,743,107.64. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Mark J. Foley sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, March 13th. The shares were sold at an average price of $55.77, for a total value of $557,700.00. Following the transaction, the insider now directly owns 220,430 shares of the company’s stock, valued at approximately $12,293,381.10. The disclosure for this sale can be found here. Company insiders own 15.60% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Legal & General Group Plc raised its position in Zeltiq Aesthetics by 7.1% in the first quarter. Legal & General Group Plc now owns 63,576 shares of the medical equipment provider’s stock worth $3,536,000 after buying an additional 4,228 shares during the period. PNC Financial Services Group Inc. raised its position in Zeltiq Aesthetics by 2.5% in the first quarter. PNC Financial Services Group Inc. now owns 5,558 shares of the medical equipment provider’s stock worth $309,000 after buying an additional 133 shares during the period. Kellner Capital LLC bought a new position in Zeltiq Aesthetics during the first quarter worth $5,683,000. California Public Employees Retirement System raised its position in Zeltiq Aesthetics by 102.4% in the first quarter. California Public Employees Retirement System now owns 145,500 shares of the medical equipment provider’s stock worth $7,222,000 after buying an additional 73,600 shares during the period. Finally, Teachers Advisors LLC raised its position in Zeltiq Aesthetics by 5.0% in the first quarter. Teachers Advisors LLC now owns 61,241 shares of the medical equipment provider’s stock worth $3,406,000 after buying an additional 2,919 shares during the period.

Zeltiq Aesthetics Company Profile

ZELTIQ Aesthetics, Inc is a medical technology company. The Company focuses on developing and commercializing products utilizing its controlled-cooling technology platform. The Company’s product, the CoolSculpting System, is designed to reduce stubborn fat bulges. The Company sells its CoolSculpting system primarily to dermatologists, plastic surgeons, aesthetic specialists and obstetrics and gynecology (OBGYN) physicians.

Related posts

Leave a Comment